CN116790680A - Method for constructing male sterile animal model and application - Google Patents

Method for constructing male sterile animal model and application Download PDF

Info

Publication number
CN116790680A
CN116790680A CN202310724778.6A CN202310724778A CN116790680A CN 116790680 A CN116790680 A CN 116790680A CN 202310724778 A CN202310724778 A CN 202310724778A CN 116790680 A CN116790680 A CN 116790680A
Authority
CN
China
Prior art keywords
sgrna
animal model
male sterile
kif6
constructing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202310724778.6A
Other languages
Chinese (zh)
Inventor
谢春波
谭跃球
涂超峰
何文斌
易思兵
蒙岚岚
谭琛
程德华
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Guang Xiu Gao Xin Life Science Co ltd Hunan
Reproductive and Genetic Hospital of CITIC Xiangya Co Ltd
Original Assignee
Guang Xiu Gao Xin Life Science Co ltd Hunan
Reproductive and Genetic Hospital of CITIC Xiangya Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Guang Xiu Gao Xin Life Science Co ltd Hunan, Reproductive and Genetic Hospital of CITIC Xiangya Co Ltd filed Critical Guang Xiu Gao Xin Life Science Co ltd Hunan
Priority to CN202310724778.6A priority Critical patent/CN116790680A/en
Publication of CN116790680A publication Critical patent/CN116790680A/en
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/87Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/89Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microinjection
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027New or modified breeds of vertebrates
    • A01K67/0275Genetically modified vertebrates, e.g. transgenic
    • A01K67/0276Knock-out vertebrates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/0004Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/16Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22Ribonucleases RNAses, DNAses
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6888Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00Genetically modified animals
    • A01K2217/07Animals genetically altered by homologous recombination
    • A01K2217/075Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00Genetically modified animals
    • A01K2217/15Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00Animals characterised by species
    • A01K2227/10Mammal
    • A01K2227/105Murine
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00Animals characterised by purpose
    • A01K2267/03Animal model, e.g. for test or diseases
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/20Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/124Animal traits, i.e. production traits, including athletic performance or the like
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/156Polymorphic or mutational markers

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Environmental Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Plant Pathology (AREA)
  • Endocrinology (AREA)
  • Pathology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Animal Husbandry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The application provides a construction method and application of a male sterile animal model. The construction method constructs an animal model simulating the human KIF6c.1325_1326del mutation through a CRISPR/Cas9 system. The male sterile animal model constructed by the method shows obvious abnormal sperm morphology and motility, can be used for researching a molecular mechanism of spermatogenesis disorder caused by KIF6 defect, and provides clinical treatment thought and strategy for patients carrying the gene defect.

Description

Method for constructing male sterile animal model and application
Technical Field
The application relates to the technical field of animal models, in particular to a construction method and application of a male sterile animal model.
Background
Infertility is not only a global medical problem, but also a serious challenge facing the current population and health area. In infertility, male factors account for about 50%, and are often manifested as semen quality abnormalities such as azoospermia, oligospermia, teratospermia. Clinically, the etiology leading to male infertility is very complex, mainly comprising: genetic factors, environmental factors, infectious factors, immune factors, and the like, wherein genetic factors including genetic mutation are important causes of male sterility.
In recent years, the rapid development of high throughput sequencing methods has led to the identification of a number of candidate novel genes associated with male sterility. But these genes would lead to male infertility? How do these genes lead to male infertility? The related problems are to be further studied and explained.
Disclosure of Invention
Based on the above, the application provides a construction method and application of a male sterile animal model simulating human KIF6c.1325_1326del mutation. The male sterile animal model constructed by the method shows obvious abnormal sperm morphology and motility, can be used for researching a molecular mechanism of spermatogenesis disorder caused by KIF6 defect, and provides clinical treatment thought and strategy for patients carrying the gene defect.
The specific technical scheme is as follows:
according to one aspect of the present application, a method of constructing a male sterile animal model is provided that constructs an animal model that mimics the human kif6c.1325_1326del mutation by a CRISPR/Cas9 system.
In one embodiment, the animal used to prepare the male sterile animal model is a mouse; the construction method is used for constructing a male sterile animal model by knocking out the 13 th exon and the 14 th exon of the mouse KIF6 gene through a CRISPR/Cas9 system.
In one embodiment, the construction method comprises the steps of:
designing a first sgRNA recognition fragment and a second sgRNA recognition fragment for the upstream of KIF6 exon13 and downstream of exon14 of the mouse, respectively;
transferring the first sgRNA, the second sgRNA, and Cas9mRNA into a fertilized mouse egg;
transplanting the fertilized eggs into a surrogate female mouse to produce F0 generation; and
Mating the F0 generation with a wild type to obtain an F1 generation heterozygote, and selfing the F1 generation heterozygote to obtain an F2 generation homozygous mutant mouse.
In one embodiment, the nucleotide sequence of the first sgRNA recognition fragment is shown in SEQ ID No. 1; the nucleotide sequence of the second sgRNA recognition fragment is shown as SEQ ID NO. 2.
In one embodiment, the construction method further comprises the steps of:
synthesizing a first double-stranded DNA comprising the first sgRNA recognition fragment and a second double-stranded DNA comprising the second sgRNA recognition fragment;
constructing a first expression vector containing the first double-stranded DNA and a second expression vector containing the second double-stranded DNA;
extracting the DNA of the first expression vector and the second expression vector; and
And taking the DNA of the first expression vector and the second expression vector as a transcription template to obtain the mRNA of the first sgRNA and the mRNA of the second sgRNA.
In one embodiment, the step of synthesizing the first double-stranded DNA and the second double-stranded DNA comprises:
adding a sticky end sequence to the 5' end of the first sgRNA recognition fragment to form a fragment with a nucleotide sequence shown as SEQ ID NO. 3; adding cohesive end sequences at two ends of the complementary sequence of the first sgRNA recognition fragment to form a fragment with a nucleotide sequence shown as SEQ ID NO. 4; annealing the first sgRNA with the sticky end and the complementary sequence with the sticky end to form a first double-stranded DNA;
adding a sticky end sequence to the 5' end of the second sgRNA recognition fragment to form a fragment with a nucleotide sequence shown as SEQ ID NO. 5; adding cohesive end sequences at two ends of the complementary sequence of the second sgRNA recognition fragment to form a fragment with a nucleotide sequence shown as SEQ ID NO. 6; annealing the cohesive terminated second sgRNA and its cohesive terminated complementary sequence to form a second double stranded DNA.
In one embodiment, the Cas9mRNA is synthesized by:
providing a linearized Cas9 expression vector as a transcription template;
and (3) performing in vitro transcription by using a primer pair with nucleotide sequences shown as SEQ ID NO. 7-8 to synthesize the Cas9mRNA.
In one embodiment, the construction method further comprises the steps of:
the primer pair with the nucleotide sequence shown as SEQ ID NO. 9-10 is used for identifying the genotype of the F1 generation heterozygote.
In one embodiment, the construction method further comprises the steps of:
the primer pair with the nucleotide sequence shown as SEQ ID NO. 9-12 is used for identifying the genotype of the F2 generation homozygote.
According to another aspect of the application, there is provided an application of a male sterile animal model constructed by the above-mentioned method for constructing a male sterile animal model in screening a drug for treating a disease associated with male sterility.
Compared with the prior art, the application has the following beneficial effects:
applicant found from studies that male sterile patients with oligospermia carry KIF6 (nm_ 145027): a double allele mutation of 1325_6del (p.T442Sfs.3) which causes the KIF6 protein to introduce a stop codon at the 442 th amino acid site, the encoded protein is truncated; based on the above, a mouse mutation model with protein variation similar to the KIF6 mutation is constructed, and can be used for researching the function of the KIF6 gene in the spermatogenesis process.
Drawings
In order to more clearly illustrate the embodiments of the present application or the technical solutions in the prior art, the drawings that are needed in the description of the embodiments or the prior art will be briefly described, and it is obvious that the drawings in the description below are some embodiments of the present application, and other drawings can be obtained according to the drawings without inventive effort for a person skilled in the art.
FIG. 1 is a schematic diagram of a mouse model constructed using CRISPR/Cas9 technology to mimic the KIF6c.1325_1326del (p.T442S fs 3) mutation carried by male sterile patients;
FIG. 2 is a western blot diagram demonstrating that both patients with a KIF6c.1325_1326del (p.T442Sfs.3) mutation and mutations carried by mutant mice can produce truncated proteins;
FIG. 3 is a plasmid map of pX 330;
FIG. 4 is a graph of agarose gel electrophoresis detection of the F1 generation of the KIF6 mutant mouse model;
FIG. 5 is a plot of the sequencing peaks for the F1 generation of the KIF6 mutant mouse model;
FIG. 6 is a schematic representation of the localization of an identification primer to the KIF6 gene;
FIG. 7 is a graph showing the genotyping results for the F2 generation of the mutant KIF6 mouse model;
FIG. 8 is a graph of fertility identification results for KIF6 mutant mice;
FIG. 9 shows the detection of the KIF6 gene in different mice by RT-PCRExpression; a is gel electrophoresis detection diagram of RT-PCR amplified product, and B is Kif6 mut/mut Mice and Kif6 wt/mut A KIF6 expression analysis result graph of mice;
FIG. 10 shows Kif6 wt/wt Mouse, kif6 wt/mut Mice and Kif6 mut/mut Comparison figures of body types of mice;
FIG. 11 is a graph of testicular tissue size and statistical analysis of different mice;
FIG. 12 shows Kif6 mut/mut Mice and Kif6 wt/mut Comparison graphs of the number, morphology and motility of epididymal sperm of mice; a is a statistical analysis chart of the number of sperms, B is a statistical analysis chart of the proportion of sperms moving forward, C is a statistical analysis chart of the curve movement speed of sperms, D is a statistical analysis chart of the linear movement speed of sperms, E is a statistical analysis chart of the average movement speed of sperms, F is a statistical analysis chart of the average swing amplitude of sperms, G is a statistical analysis chart of the proportion of sperms moving linearly on average, and H is a statistical analysis chart of the proportion of sperms at rest.
Detailed Description
The detailed description of the present application will be provided to make the above objects, features and advantages of the present application more obvious and understandable. In the following description, numerous specific details are set forth in order to provide a thorough understanding of the present application. The present application may be embodied in many other forms than described herein and similarly modified by those skilled in the art without departing from the spirit of the application, whereby the application is not limited to the specific embodiments disclosed below.
Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this application belongs. The terminology used herein in the description of the application is for the purpose of describing particular embodiments only and is not intended to be limiting of the application. Unless otherwise specifically indicated, the various raw materials, reagents, instruments, equipment and the like used in the present application are commercially available or may be prepared by existing methods.
CRISPR is an adaptive immune system of bacteria and archaea against phage infection. In this system, single-stranded guide RNAs (sgrnas) direct endonucleases to specific genomic sequences and cleave DNA near PAM sequences (protospacer adjacent motif) to form Double-strand-DNA breaks (DSBs), which can then be used to introduce mutation information in exogenous templates into genomic DNA using homologous recombination repair mechanisms.
WES (whole exome sequencing ): the method is characterized in that the sequence capturing technology is utilized to capture and enrich the DNA of the exon region of the whole genome, and then high-throughput sequencing is carried out, so that genetic variation SNP (single nucleotide polymorphism) related to protein functional variation can be directly found.
RT-PCR (reverse transcription-polymerase chain reaction, reverse transcription polymerase chain reaction: a technique combining reverse transcription (reverse transcription) of RNA and polymerase chain amplification (PCR) of cDNA, firstly extracting total RNA in tissues or cells, using mRNA therein as a template, reverse transcription into cDNA using Oligo (dT) or random primers, and then carrying out PCR amplification using cDNA as a template to obtain a target gene or detect gene expression.
Applicant found a double allelic mutation (c1325_ 1326del[p.T442S fs*3) of kinesin family member KIF6 (Kinesin family member, kinesin family member 6) in 1 patient with oligospermia infertility by whole exome sequencing (whole exome sequencing, WES)]). KIF6 was originally thought to be a coronary heart disease susceptibility gene, but subsequent studies confirmed that this association did not exist; zebra fish with KIF6 mutations survived without significant heart defects, but juvenile scoliosis was found. In 2018, konjikusic et al identified homozygous frameshift mutations in KIF6 gene in 1 male infant suffering from neurodevelopmental disorder and mental disorder, KIF6 knockout mice did not have heart abnormality-related phenotype, but exhibited severe hydrocephalus due to ventricular cilia defect. Konjikuic et al constructed Kif6 by CRISPR-Cas9 p.G555fs Mutant mice, all homozygous mutant mice (7) developed hydrocephalus phenotype at 14 days post-natal and became severe with age; at 28 days, the brain of the mutant mice was significantly larger than the littermate control group,therefore, it was not experimentally observed in mice 28 days later (45 days were required for completion of the first wave of spermatogenesis in mice), and it was not clear whether KIF6 gene deficiency was the cause of spermatogenesis disorder and male infertility. Thus, it is unclear whether mutations in the KIF6 gene affect spermatogenesis, which in turn leads to male infertility.
Based on this, some embodiments of the present application provide a method of constructing a male sterile animal model.
In some of these embodiments, the above-described methods of constructing a male sterile animal model construct an animal model that mimics the human KIF6c.1325_1326del mutation via a CRISPR/Cas9 system.
The applicant found through research that male sterile patients with clinical oligospermia and teratospermia carry a biallelic mutation of kif6c.1325_1326del (p.t442s fs 3), which causes KIF6 protein to introduce a stop codon at amino acid position 442, and protein truncation occurs. An animal model is constructed based on the protein variation caused by the mutation site, and can be used for researching whether the KIF6 gene is associated with male sterility related diseases.
In some embodiments, the animal used to prepare the male sterile animal model is a mouse.
In some of these embodiments, the male sterile animal model is constructed by knocking out exon13 and exon14 of the mouse KIF6 gene.
Bioinformatics prediction shows that after knocking out the 13 th to 14 th exons of the mouse KIF6 gene, the coded KIF6 protein introduces a stop codon at 486 th amino acid site, so that the translated KIF6 protein is truncated. The KIF6 protein encoded by the KIF6 c.1325_6del mutation is obtained by introducing a stop codon at the 442 th amino acid position, so that the translated KIF6 protein is truncated. Both are loss-of-function mutations, so animal models constructed by knocking out exons 13 to 14 of the mouse KIF6 gene can mimic the human KIF6c.1325_1326del mutation and be used to explore the role of the gene in spermatogenesis.
In some embodiments, the method for constructing a male sterile animal model comprises the following steps:
designing a first sgRNA recognition fragment and a second sgRNA recognition fragment for the upstream of KIF6 exon13 and downstream of exon14 of the mouse, respectively; and
Transferring the first sgRNA, the second sgRNA and Cas9mRNA into a fertilized egg of a mouse;
transplanting fertilized eggs into a surrogate female mouse to produce F0 generation; and
Mating the F0 generation with a wild type to obtain an F1 generation heterozygote, and selfing the F1 generation heterozygote to obtain an F2 generation homozygous mutant mouse.
The sgrnas between 2 coiled-coil domains of the mouse KIF6 protein were targeted to obtain a truncated protein comprising only the N-terminal driving motor domain and 1 coiled-coil domain near the N-terminal, capable of mimicking the biallelic mutation (c1325_ 1326del[p.T442S fs*3) of KIF6 in male sterile patients.
In some specific examples, the nucleotide sequence of the first sgRNA recognition fragment is shown in SEQ ID No. 1; the nucleotide sequence of the second sgRNA recognition fragment is shown in SEQ ID NO. 2.
Specifically, the nucleotide sequence shown in SEQ ID NO.1 is: 5'-GACCCGTCATTAAGTTGACA-3'; the nucleotide sequence shown in SEQ ID NO.2 is: 5'-ACCCTATCAATTGTACCTGG-3'.
By adopting the two sgRNA recognition fragments of the specific sequences, specific knockout and knock-in of the specific sequences of the 13 th and 14 th exons of the mouse KIF6 gene can be rapidly and accurately carried out, and the KIF6 (NM_ 145027) carried by male sterile patients can be simulated: 1325_1326del (p.t442s fs 3) biallelic mutation.
In some specific examples, the above construction method further includes the following steps:
synthesizing a first double-stranded DNA comprising a first sgRNA recognition fragment and a second double-stranded DNA comprising a second sgRNA recognition fragment;
constructing a first expression vector containing a first double-stranded DNA and a second expression vector containing a second double-stranded DNA;
extracting the DNA of the first expression vector and the second expression vector; and
And taking the DNA of the first expression vector and the second expression vector as transcription templates to obtain the mRNA of the first sgRNA and the mRNA of the second sgRNA.
In some specific examples, the step of synthesizing the first double-stranded DNA and the second double-stranded DNA includes:
adding a sticky end sequence to the 5' end of the first sgRNA recognition fragment to form a fragment with a nucleotide sequence shown as SEQ ID NO. 3; adding cohesive end sequences at two ends of the complementary sequence of the first sgRNA recognition fragment to form a fragment with a nucleotide sequence shown as SEQ ID NO. 4; annealing the first sgRNA with the sticky end and the complementary sequence with the sticky end to form a first double-stranded DNA;
adding a sticky end sequence to the 5' end of the second sgRNA recognition fragment to form a fragment with a nucleotide sequence shown as SEQ ID NO. 5; adding cohesive end sequences at two ends of the complementary sequence of the second sgRNA recognition fragment to form a fragment with a nucleotide sequence shown as SEQ ID NO. 6; annealing the cohesive terminated second sgRNA and its cohesive terminated complementary sequence to form a second double stranded DNA.
Specifically, the nucleotide sequence shown in SEQ ID NO.3 is:
5’-CACCTAATACGACTCACTATAGGGGACCCGTCATTAAGTTGACA-3’;
the nucleotide sequence shown in SEQ ID NO.4 is:
5’-AAACTTGTCAACTTAATGACGGGTCCCCTATAGTGAGTCGTATTA-3’;
the nucleotide sequence shown in SEQ ID NO.5 is:
5’-CACCTAATACGACTCACTATAGGGACCCTATCAATTGTACCTGG-3’;
the nucleotide sequence shown in SEQ ID NO.6 is:
5’-AAACTCCAGGTACAATTGATAGGGTCCCTATAGTGAGTCGTATTA-3’。
mRNA for the sgRNA is obtained by constructing an expression vector containing the recognition fragment of the sgRNA and transcribing it in vitro.
In some specific examples thereof, the Cas9mRNA described above is synthesized by:
providing a linearized Cas9 expression vector as a transcription template;
and (3) performing in vitro transcription by using a primer pair with nucleotide sequences shown as SEQ ID NO. 7-8 to synthesize the Cas9mRNA.
Specifically, the nucleotide sequence shown in SEQ ID NO.7 is:
5’-TTAATACGACTCACTATAGGGATGGACTATAAGGACCACGAC-3’;
specifically, the nucleotide sequence shown in SEQ ID NO.8 is:
5’-GCGAGCTCTAGGAATTCTTAC-3’。
in some specific examples, the above construction method further includes the following steps: the primer pair with the nucleotide sequence shown as SEQ ID NO. 9-10 is used for identifying the genotype of the F1 generation mice.
Specifically, the nucleotide sequence shown in SEQ ID NO.9 is:
5’-TGTTCTGAGTAGTAGCCATCTCT-3’;
the nucleotide sequence shown in SEQ ID NO.10 is:
5’-TGTGCAAGCATCTAATCCATCAC-3’。
in some specific examples, the above construction method further includes the following steps: the primer pair with the nucleotide sequence shown as SEQ ID NO. 9-12 is used for identifying the genotype of the F2-generation mice.
Specifically, the nucleotide sequence shown in SEQ ID NO.11 is:
5’-CTAAGGCATTTAGCCTGGGAGAA-3’;
specifically, the nucleotide sequence shown in SEQ ID NO.12 is:
5’-GGTACCCTCGCTTGCTTACTC-3’。
in some specific examples, the method of identification described above is PCR amplification or Sanger sequencing.
The method for constructing the male sterile animal model has at least the following advantages:
by targeting sgrnas between 2 coiled-coil domains of the mouse KIF6 protein to obtain a truncated protein comprising only the N-terminal kinesin motor domain and 1 coiled-coil domain near the N-terminal, a male sterile animal model of KIF6 gene mutation was constructed that was able to mimic the biallelic mutation (c1325_ 1326del[p.T442S fs*3) of KIF6 in male sterile patients.
Compared with the wild type, the sperm proportion of forward movement, curve movement, linear movement, average movement speed, average swing amplitude and average linear movement of the sperm in the male sterile animal model constructed by the method is reduced, and the sperm proportion of the static sperm is obviously increased. The surface male sterile animal model can be used for researching and analyzing the molecular mechanism of spermatogenesis disorder, and provides a new idea for diagnosis and treatment of male sterile patients.
Some embodiments of the application also provide an application of the male sterile animal model constructed by the method in screening medicines for treating male sterility related diseases.
The present application will be further described with reference to specific examples and comparative examples, which should not be construed as limiting the scope of the application.
Example 1: construction of KIF6 mutant mouse model
(1) Preliminary localization of sgrnas
Human KIF6 protein consists of 814 amino acids, including 1 kinesin motor domain (Kinesin motor domain) and 3 coded-coil domains, patient KIF6 (nm_ 145027): the 1325_1326del (p.t442s fs 3) mutation results in the production of truncated proteins (comprising only the N-terminal kinesin motor domain and 1 coiled-coil domain near the N-terminal). The mouse KIF6 protein consists of 802 amino acids, including 1 kinesin motor domain (Kinesin motor domain) and 2 coiled-coil domains.
Further, applicants utilized CRISPR/Cas9 technology to mimic KIF6 (nm_ 145027) found by WES sequencing in 1 case of feeble teratospermia male infertility patients: double allele mutation of 1325_1326del (p.T442Sfs.3) construction of KIF6 Gene mutant mice (Kif6) mut/mut ) 2 sgrnas were designed to target the Exon13 upstream and Exon14 downstream of KIF6 gene, respectively, to disrupt the 1 coiled-coil domain near the C-terminus in the mouse KIF6 protein to obtain a truncated protein comprising only the N-terminal kinesin motor domain and 1 coiled-coil domain near the N-terminus.
Bioinformatics prediction shows that the deletion of 13 th and 14 th exons of mutant mouse KIF6 gene leads to the introduction of a stop codon into coded KIF6 protein at 486 th amino acid site, resulting in the truncation of translated KIF6 protein; the KIF6 protein encoded by the KIF6c.1325_1326del mutation introduces a stop codon at the 442 th amino acid site, so that the translated KIF6 protein is truncated (shown in FIG. 1); both are loss-of-function mutations.
In vitro overexpression plasmid transfection HEK293 cell experiments also revealed patient-carried KIF6 (nm_ 145027): both the 1325_1326del (p.t442s fs×3) mutation and the mouse carried mutant sequence resulted in truncated protein production (as shown in fig. 2). The mutant mice described above were shown to mimic the KIF6c.1325_1326del mutation in male patients and were used to study the role of KIF6 in spermatogenesis.
(2) Design of target KIF6 mutation site sgRNA
Searching for the target KIF6 (GenBank: NM-177052.3; ensembl: ENSMUST 00000162854.2) on an http:// crispor.tefor.net/website established at Zhang Feng, designing and synthesizing a first sgRNA (PAM is NGG) upstream of Exon13 for KIF6, designing and synthesizing a second sgRNA (PAM is NGG) downstream of Exon14 for KIF 6; 2 sgrnas with better cleavage efficiency and lower probability of off-target were predicted at the CCtop website. Wherein the nucleotide sequence of the first sgRNA is shown as SEQ ID NO.1, and the cleavage efficiency is 0.57; the nucleotide sequence of the second sgRNA is shown as SEQ ID NO.2, and the cleavage efficiency is 0.68.
Because the transcription of the sgRNA template requires a T7 promoter, the 5' ends of the first sgRNA and the second sgRNA are respectively added with a T7 promoter sequence, and the synthetic nucleotide sequences are shown as SEQ ID NO.3 and SEQ ID NO.5, which are respectively named as Kif6-sgRNA-1-F and Kif6-sgRNA-2-F; respectively adding cohesive ends at two ends of complementary sequences of the first sgRNA and the second sgRNA, and synthesizing sequences with nucleotide sequences shown in SEQ ID NO.4 and SEQ ID NO.6, which are respectively named as Kif6-sgRNA-1-R and Kif6-sgRNA-2-R; for transcription of sgrnas. The sequence information is shown in table 1.
TABLE 1
(3) Construction of expression vectors
The sgrnas anneal to form double stranded DNA: the transcription template sequences of the first sgRNA (Kif 6-sgRNA-1-F and Kif 6-sgRNA-1-R) and the transcription template sequences of the second sgRNA (Kif 6-sgRNA-2-F and Kif 6-sgRNA-2-R) are respectively diluted to a final concentration of 100umol/L, 10uL of each of the forward (F) and reverse (R) chains is added into a PCR tube, sealed by a sealing film, placed into 500 mL-600 mL boiled water, and naturally annealed to room temperature to form a first double-stranded DNA (dsDNA) and a second double-stranded DNA.
Tangential restriction of pX330 vector BbsI: the BbsI enzyme is utilized to tangentially linearize the pX330 cloning vector (the plasmid map of the pX330 in FIG. 3), the enzyme digestion reaction system is shown in Table 2, the prepared reaction reagents are mixed and centrifuged, and the mixture is placed into a water bath kettle at 37 ℃ for incubation for 0.5h, and the mixture is oscillated once at intervals and centrifuged to prevent liquid drops from evaporating onto a pipe cover.
TABLE 2
Name of the name Dosage of
pX330 3μg
BbsI-HF 1.5μL
10×NEBuffer 5μL
ddH 2 O Make up to 50 mu L
Ligation was performed according to the reaction system shown in Table 3, and the reaction was carried out at 16℃for 3 hours, followed by cyclization to construct an expression vector: and constructing a first expression vector by taking the first double-stranded DNA as a template, and constructing a second expression vector by taking the second double-stranded DNA as a template.
TABLE 3 Table 3
(4) In vitro transcription amplification of sgRNA
Selecting enzyme cutting sites at the downstream of the sgRNA template sequence, and linearizing the first expression vector and the second expression vector by KpnI endonuclease, wherein RNA transcripts with different lengths can be obtained by taking non-linearized circular plasmids as templates, and the enzyme cutting linearization can ensure that the sgRNA mRNA transcripts with determined lengths and sequences are obtained; the reaction system is shown in Table 4, the prepared reaction reagents are mixed and centrifuged, and the mixture is placed in a water bath kettle at 37 ℃ for incubation for 0.5h, and the mixture is oscillated and centrifuged once at intervals. And respectively extracting the DNA of the linearized first expression vector and the DNA of the linearized second expression vector to serve as templates for in vitro transcription of the sgRNA.
TABLE 4 Table 4
Composition of the components Dosage of
First expression vector or second expression vector 3μg
KpnI 1.5μL
10×NEBuffer 5μL
ddH 2 O Make up to 50 mu L
According to the step requirements of the MEGAshortscript T kit, in vitro transcription reactions were performed in PCR tubes according to the reaction system of table 5: incubation was carried out overnight at 37℃to obtain maximum yield. After the incubation was completed, 1. Mu.L of TURBO DNase was added to the system and incubated at 37℃for 15 minutes to remove the DNA template. Subsequently, phenol-chloroform extraction/NH was used 4 The first sgRNA or the second sgRNA was purified by OAc precipitation and dissolved in 10. Mu.L to 20. Mu.L RNase-free water. The sgRNA mRNA was obtained by in vitro transcription.
TABLE 5
(5) In vitro transcription of Cas9mRNA
Linearizing pX330 with NotI endonuclease, mixing the prepared reagents, centrifuging, incubating in a 37 deg.C water bath for 0.5h, oscillating once at intervals, and centrifuging.
TABLE 6
A T7 promoter is introduced into a primer for amplifying a Cas9 sequence (the primer sequence is shown in table 7), the Cas9 sequence in the linearized pX330 vector is amplified by using T7-Cas9-F/R, and the amplified product is T7-Cas9, which is used as a template for Cas9 in vitro transcription. And recovering the T7-Cas9 product using a QIAquick PCR product purification kit.
TABLE 7
Using the purified T7-Cas9 product as a template, it was transcribed into Cas9mRNA using mMESSAGE mMACHINETMT7ULTRA transcription kit: incubating for 2h at 37℃according to the transcription system configuration shown in Table 8; mu.L of TURBO DNase was added and incubated at 37℃for 30 minutes.
TABLE 8
Reagent(s) Volume of
T7 2×NTP/ARCA 10μL
10×T7 Reaction Buffer 2μL
T7-Cas9 products 1μg
T7 Enzyme Mix 2μL
Nuclease-free H 2 O Make up to 20 mu L
Poly (A) tails were added to the reaction products described above, followed by tailing reagents in the order indicated in Table 9. After mixing, 2.5. Mu.L of the mixture was removed and 4. Mu. L E-PAP was added; mixing well, incubating at 37 ℃ for 45 minutes. SubsequentlyExtraction of NH Using phenol-chloroform 4 Purifying the Cas9mRNA by OAc precipitation; the precipitate was dissolved with 10. Mu.L to 20. Mu.L RNase-free water.
TABLE 9
(6) Microinjection and identification of F0 mice: diluting the first sgRNA mRNA and the second sgRNA mRNA obtained by amplification in the step (4) and the Cas9mRNA synthesized in the step (5) respectively to obtain 25 ng/. Mu.L of the first sgRNA mRNA and the second sgRNA mRNA and 100 ng/. Mu.L of the Cas9mRNA, and taking 10 mu.L of each to obtain 30 mu.L of total microinjection mixture. Fertilized eggs are obtained from the uterus of donor female mice 0.5 days after mating, fertilized eggs with good morphology and moderate development state are selected and transferred into a culture medium of an injection dish, and microinjection mixed solution is injected into the fertilized eggs; subsequently, the fertilized eggs after microinjection are returned to the oviduct of the surrogate mice; and carrying out PCR and sequencing identification on the mice after birth to obtain positive F0-generation mice.
(7) Breeding and identification of F1 mice: and (3) breeding the neutral mature positive F0 mice in the step (6) with wild mice for one generation respectively, and carrying out PCR and sequencing verification on the F1 generation mice. The F1 mice will be used for further propagation to obtain KIF6 homozygous mutant mice (Kif 6 mut/mut )。
The targeted region of the mouse KIF6 locus was PCR amplified using specific primers shown in table 10. The accuracy of targeting was confirmed by sequencing the PCR products. Toe DNA of F1-generation mice was amplified (the successful band size for targeting was about 500bp, the wild-type band size was 75740 bp) using Kif6-F1 and Kif6-R1 primers, and FIG. 4 is a 1% agarose gel electrophoresis chart of the amplified products; FIG. 5 is a graph of the sequencing peaks of the K1 sample, wherein the sequencing results of K1, K2, K3 and K4 show that the F1 generation mice are successfully constructed.
Table 10
Sequence number Name of the name Sequence (5 '-3')
SEQ ID NO.9 Kif6-F1 TGTTCTGAGTAGTAGCCATCTCT
SEQ ID NO.10 Kif6-R1 TGTGCAAGCATCTAATCCATCAC
(8) Identification of F2 mice
F1 generation heterozygote male mouse (Kif 6) wt/mut ) After the heterozygote female mice were caged, genotype identification was performed on the F2 mice born using the primer pairs shown in Table 10 and Table 11, respectively (the localization of each primer on the KIF6 gene is shown in FIG. 6). The detection results are shown in FIG. 7 (male sex rat, female sex rat, -/-means Kif 6) mut/mut Mice, +/-refer to Kif6 wt/mut A mouse); heterozygous mice (Kif 6) wt /mut ) Two-item bands with the sizes of 500bp and 349bp can be amplified; homozygous mice (Kif 6) mut/mut ) Only the target band of 500bp in size can be amplified.
TABLE 11
Sequence number Name of the name Sequence (5 '-3')
SEQ ID NO.11 Kif6-F2 CTAAGGCATTTAGCCTGGGAGAA
SEQ ID NO.12 Kif6-R2 GGTACCCTCGCTTGCTTACTC
Example 2: detection and identification of KIF6 mutant mice
(1) Fertility detection: the toe DNA of the mice was extracted and genotyping was performed by agarose gel electrophoresis in combination with Sanger sequencing. Kif6 was used mut/mut Male mice were housed in wild female mice for 3 months, and Kif6 was evaluated mut/mut Whether the male mice are fertile. The results are shown in FIG. 8, which shows the results with Kif6 wt/wt Male mouse and Kif6 wt/mut Compared with male mice, kif6 mut/mut Male mice were completely sterile.
(2)Kif6 mut/mut Male mouse phenotype identification: 3 wild male mice (Kif 6) wt/wt ) Heterozygous male mouse (Kif 6) wt/mut ) And homozygous mutant male mice (Kif 6) mut/mut ) Photographing and weighing, and observing the development condition of the mutant mice; next, kif6wt/mut male mice and Kif6 were taken separately mut/mut Shooting and weighing testis and epididymal tissues of male mice, and performing statistical analysis; simultaneously, RNA extraction is carried out on testis tissues, and the testis tissues are used for verifying the expression level of KIF6 by RT-PCR. The results are shown in FIG. 9, kif6 mut/mut Failure to detect expression of KIF6 gene in male mice; as shown in FIG. 10, with Kif6 wt/wt Male mouse and Kif6 wt/mut In comparison to male mice, most mutant mice showed no significant abnormalities in growth development (signs and body weight), and only 20% (2/10) of the mutant mice exhibited a hydrocephalus phenotype. As shown in FIG. 11, kif6 mut/mut Male mouse testisAnd epididymal size was not seen as significant abnormalities.
(3) Sperm motility analysis: using CASA (Computer-aided sperm analysis, computer assisted sperm analysis) camera system to obtain 8-10 week old epididymal sperm of mice, comparing Kif6 mut/mut Male mouse and Kif6 wt/mut Motion ability of epididymal sperm of male mouse, and statistical analysis of Kif6 mut/mut Whether the number, the motility and the movement track of the epididymal sperm of the mice are abnormal or not.
The results are shown in FIG. 12, which shows the results with Kif6 wt/mut Compared with male mice, kif6 mut/mut The number of epididymal sperms of the male mice is obviously reduced (A); and Kif6 mut/mut The sperm proportion (B), the curve movement speed (C), the linear movement speed (D), the average movement speed (E), the average swing amplitude (F) and the average linear movement sperm proportion (G) of the epididymis of the male mouse are higher than those of Kif6 wt/mut Male mice were significantly reduced, while resting sperm count (H) was lower than Kif6 wt/mut The male mice were significantly increased.
The results indicate that KIF6 is involved in the regulation of sperm motility; the KIF6 mutant mice constructed by the application can be used for further exploring the molecular mechanism of the spermatogenesis disorder caused by the KIF6 defect and the treatment strategy of the patient carrying the gene defect.
The technical features of the above-described embodiments may be arbitrarily combined, and all possible combinations of the technical features in the above-described embodiments are not described for brevity of description, however, as long as there is no contradiction between the combinations of the technical features, they should be considered as the scope of the description.
The above examples illustrate only a few embodiments of the application, which are described in detail and are not to be construed as limiting the scope of the application. It should be noted that it will be apparent to those skilled in the art that several variations and modifications can be made without departing from the spirit of the application, which are all within the scope of the application. Accordingly, the scope of protection of the present application is to be determined by the appended claims.

Claims (10)

1. A method for constructing a male sterile animal model, which is characterized in that the method constructs an animal model simulating human KIF6c.1325_1326del mutation through a CRISPR/Cas9 system.
2. The method for constructing a male sterile animal model according to claim 1, wherein the animal used for preparing the male sterile animal model is a mouse; the construction method constructs the male sterile animal model by knocking out the 13 th exon and the 14 th exon of the mouse KIF6 gene.
3. The method for constructing a male sterile animal model according to claim 2, wherein the method for constructing comprises the steps of:
designing a first sgRNA recognition fragment and a second sgRNA recognition fragment aiming at the upstream of a 13 th exon and the downstream of a 14 th exon of a mouse KIF6 gene respectively;
transferring the first sgRNA, the second sgRNA, and Cas9mRNA into a fertilized mouse egg;
transplanting the fertilized eggs into a surrogate female mouse to produce F0 generation; and
Mating the F0 generation with a wild type to obtain an F1 generation heterozygote, and selfing the F1 generation heterozygote to obtain an F2 generation homozygous mutant mouse.
4. The method for constructing a male sterile animal model according to claim 3, wherein the nucleotide sequence of the first sgRNA recognition fragment is shown in SEQ ID No. 1; the nucleotide sequence of the second sgRNA recognition fragment is shown as SEQ ID NO. 2.
5. The method for constructing a male sterile animal model according to claim 3, further comprising the steps of:
synthesizing a first double-stranded DNA comprising the first sgRNA recognition fragment and a second double-stranded DNA comprising the second sgRNA recognition fragment;
constructing a first expression vector containing the first double-stranded DNA and a second expression vector containing the second double-stranded DNA;
extracting the DNA of the first expression vector and the second expression vector; and
And taking the DNA of the first expression vector and the second expression vector as a transcription template to obtain the mRNA of the first sgRNA and the mRNA of the second sgRNA.
6. The method of constructing a male sterile animal model according to claim 5, wherein the step of synthesizing the first double-stranded DNA and the second double-stranded DNA comprises:
adding a sticky end sequence to the 5' end of the first sgRNA recognition fragment to form a fragment with a nucleotide sequence shown as SEQ ID NO. 3; adding cohesive end sequences at two ends of the complementary sequence of the first sgRNA recognition fragment to form a fragment with a nucleotide sequence shown as SEQ ID NO. 4; annealing the first sgRNA with the sticky end and the complementary sequence with the sticky end to form a first double-stranded DNA;
adding a sticky end sequence to the 5' end of the second sgRNA recognition fragment to form a fragment with a nucleotide sequence shown as SEQ ID NO. 5; adding cohesive end sequences at two ends of the complementary sequence of the second sgRNA recognition fragment to form a fragment with a nucleotide sequence shown as SEQ ID NO. 6; annealing the cohesive terminated second sgRNA and its cohesive terminated complementary sequence to form a second double stranded DNA.
7. The method of constructing a male sterile animal model according to any one of claims 3 to 6, wherein the Cas9mRNA is synthesized by:
providing a linearized Cas9 expression vector as a transcription template;
and (3) performing in vitro transcription by using a primer pair with nucleotide sequences shown as SEQ ID NO. 7-8 to synthesize the Cas9mRNA.
8. The method for constructing a male sterile animal model according to any one of claims 3 to 6, further comprising the steps of:
the primer pair with the nucleotide sequence shown as SEQ ID NO. 9-10 is used for identifying the genotype of the F1 generation heterozygote.
9. The method for constructing a male sterile animal model according to any one of claims 3 to 6, further comprising the steps of:
the primer pair with the nucleotide sequence shown as SEQ ID NO. 9-12 is used for identifying the genotype of the F2 generation homozygote.
10. Use of a male sterile animal model constructed by the method for constructing a male sterile animal model according to any one of claims 1 to 9 for screening a medicament for treating a male sterility-related disease.
CN202310724778.6A 2023-06-19 2023-06-19 Method for constructing male sterile animal model and application Pending CN116790680A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202310724778.6A CN116790680A (en) 2023-06-19 2023-06-19 Method for constructing male sterile animal model and application

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202310724778.6A CN116790680A (en) 2023-06-19 2023-06-19 Method for constructing male sterile animal model and application

Publications (1)

Publication Number Publication Date
CN116790680A true CN116790680A (en) 2023-09-22

Family

ID=88043082

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202310724778.6A Pending CN116790680A (en) 2023-06-19 2023-06-19 Method for constructing male sterile animal model and application

Country Status (1)

Country Link
CN (1) CN116790680A (en)

Similar Documents

Publication Publication Date Title
CN107287245B (en) Construction method of Glrx1 gene knockout animal model based on CRISPR/Cas9 technology
WO2018177351A1 (en) Method for preparing non-chimeric gene knockout animal based on crispr/cas9 technology
CN110551759B (en) Composition and method for improving recombination efficiency of transgenic cells
Hisanaga et al. Deep evolutionary origin of gamete-directed zygote activation by KNOX/BELL transcription factors in green plants
CN106282231B (en) Construction method and application of mucopolysaccharide storage disease type II animal model
CN113088521A (en) Construction method of Ahnak2 gene knockout animal model based on CRISPR/Cas9 technology
CN113234756A (en) Construction method of LAMA3 gene knockout animal model based on CRISPR/Cas9 technology
CN114480497B (en) Construction and application method of ep400 gene knockout zebra fish heart failure model
CN116790680A (en) Method for constructing male sterile animal model and application
CN115029352A (en) Method for breeding adgrg1 gene-deleted zebra fish through gene knockout
CN114085840A (en) Construction method of CAMTA2 gene-deleted zebra fish
CN108330130B (en) sgRNA, Gal antigen-deleted rabbit model prepared from sgRNA and application of sgRNA
CN111793653B (en) Construction method of dpy19l1l gene deletion type zebra fish
CN110438159A (en) A kind of construction method for the mutant mouse model causing muscle fibril myopathy
CN114410691B (en) Construction method and application of SLC35E1 gene knockout mouse animal model
CN114250247B (en) Construction method and application of GLUD1 mutant gene knock-in mouse animal model
CN111621500B (en) Rat model for atrial fibrillation/atrial cardiomyopathy based on MYL4 gene editing and construction method thereof
CN108165640B (en) SNP locus related to resistance or susceptibility of diarrhea of suckling piglet and molecular marker detection and application
CN117887760A (en) Knock-in mouse model of novel pathogenic mutation c.1143delC of SQSTM1/p62 gene and construction method thereof
CN118356496A (en) Application of UHRF1 and gene thereof as target in improving in-vitro embryo development rate of assisted reproduction
CN113122581A (en) Establishment and application of Hsf1 gene knockout mouse model
CN117859703A (en) Knock-in mouse model of new mutation pathogenic site C104G of Anxa11 gene, and construction method and application thereof
CN116064559A (en) Construction method of nonomo gene deletion type zebra fish
CN116676335A (en) CHRDL1 gene knock-in mouse model and construction method thereof
CN117327697A (en) Nucleic acid composition of targeted Tekt4 gene, construction method and application of animal model of weak teratospermia

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination